IRLAB Therapeutics achieved significant advancement in its Parkinson's disease pipeline, with positive Phase I data for IRL757 and receipt of a $2.5 million milestone payment in Q4 2024.
IRLAB's Phase IIb study of pirepemat for balance and falls in Parkinson's patients is fully enrolled, showing a reduction in falls during blinded data observation.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.